(Q34597143)

3 August 2017

1 reference

title

HER2/neu in the management of invasive breast cancer (English)

1 reference

3 August 2017

4

Kelly K Hunt

1 reference

3 August 2017

3

Gabriel N Hortobagyi

1 reference

3 August 2017

2

Mien-Chie Hung

1 reference

3 August 2017

Funda Meric

1

1 reference

3 August 2017

publication date

1 April 2002

1 reference

Journal of the American College of Surgeons

3 August 2017

published in

1 reference

3 August 2017

volume

194

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

488-501

1 reference

3 August 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Oral cancer progression and c-erbB-2/neu proto-oncogene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Molecular mechanisms underlying ErbB2/HER2 action in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

ERBB2 oncogene in human breast cancer and its clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Recommendations for HER2 testing in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Differences in estrogen receptor status, HER2, and p53 comparing metachronous bilateral breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Stability of HER-2/neu expression over time and at multiple metastatic sites

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

HER-2/neu oncogene protein and prognosis in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

The long term prognostic significance of c-erbB-2 in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

C-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

The association of HER-2/neu amplification with breast cancer recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Selection of peptides and synthesis of pentameric peptabody molecules reacting specifically with ErbB-2 receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the her-2/neu (c-erbB-2) gene

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Retinoids control the expression of c-erbB receptors in breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

1 reference

7 January 2021

First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2802%2901121-3

7 January 2021

10.1016/S1072-7515(02)01121-3

Identifiers

DOI

1 reference

3 August 2017

1 reference